In patients with EGFR-mutated NSCLC, the current standard of care in the first-line setting is the third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib [5,6,7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.